Supriya Lifescience Ltd

Stage 2 · Advancing · week 1Setup 7.0 ★★ GoodStrong +6.5

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. More about the company

₹889.3
-2.85% today
₹7,157 Cr · Mid cap
Market Neutral — FadingHealth Care 45.7% in Stage 2-1.4 pts / 20dPharmaceuticals 53.8%+3.8 pts
Loading price chart…
vs 52W High
-15.5%
₹553.4 lo₹1,052.5 hi
15.5% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 1
1w13w26w
Week 1 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
14.6%
200 DMA: ₹776.2 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.50x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑ ⇈
Accelerating · MA20 +7.5% vs MA50 +2.3% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
+4.3%
3M
+3.2%
6M
+44.5%
YTD
+18.7%
1Y
+26.7%
Sector
Health Care
↓ Peaking
Stage 2%
45.7%
20d Δ
-1.4pp
1M return
-1.8%
3M return
+4.4%
Sector Stage-2 % · last 20 days
This stock ranks #41 of 77 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
↑ Building
Stage 2%
53.8%
20d Δ
+3.8pp
1M return
-0.9%
3M return
+3.6%
Industry Stage-2 % · last 20 days
Ranks #35 of 61 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-11 → 2026-10-07
S2 15w
S2 59w
S2 13w
2023-07-112026-10-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 15w → S3 8w → S2 59w → S3 9w → S2 3w → S3 2w → S2 5w → S3 3w → S2 3w → S4 9w → S1 1w → S2 13w → S3 5w → S4 11w → S1 3w → S2 11w → S3 5w → S2 1w current
Total tracked: 168 weeks across 18 stage runs.
Scan Membership
Prop Scan
Latest: 2026-10-07
Breakout Watch
Latest: 2026-09-30
Pullback Hunter
Latest: 2026-07-14
41 appearances in last 60 days. First seen: 2025-04-16.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-07S2
Wk 1 · Vol 0.50x
2026-10-06S2
Wk 1 · Vol 0.53x
2026-10-05S2
Wk 1 · Vol 1.06x
2026-10-01S2
Wk 1 · Vol 0.63x
2026-09-30S23→2
Wk 1 · Vol 0.70x
2026-09-29S3
Wk 6 · Vol 1.71x
2026-09-28S3
Wk 5 · Vol 1.39x
2026-09-25S3
Wk 5 · Vol 1.04x
2026-09-24S3
Wk 5 · Vol 0.79x
2026-09-23S3
Wk 5 · Vol 3.39x
2026-09-22S3
Wk 5 · Vol 1.13x
2026-09-21S3
Wk 4 · Vol 1.66x
Sector Peers — Stage 2All →
KOPRAN
wk 19 · -5.0% from hi
9.0
SMSPHARMA
wk 3 · -3.0% from hi
8.7
KILITCH
wk 2 · -1.7% from hi
8.7
BAFNAPH
wk 17 · 0.0% from hi
8.6
ZIMLAB
wk 21 · 0.0% from hi
8.3
Moving averages & range
50 DMA
₹874.3
200 DMA
₹776.2
52W High
₹1,052.5
52W Low
₹553.4
5D Low
₹889.3
Resistance levels (recent highs)
20d High
₹1,000.9
60d High
₹1,000.9
120d High
₹1,052.5
250d High
₹1,052.5
Next resistance
+12.6%
to 20d High
Ask the Market AI about SUPRIYAAsk →
P/E (TTM)
35.0
Forward 26.5
Earnings Growth (YoY)
+6.0%
Revenue +11.2%
Dividend Yield
0.13%
P/B 6.0
About this companyHealth Care· Pharmaceuticals

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.